Compare GANX & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GANX | CMT |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | 1570 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 164.4M |
| IPO Year | 2021 | 1996 |
| Metric | GANX | CMT |
|---|---|---|
| Price | $2.59 | $18.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 592.8K | 16.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.95 | N/A |
| EPS | N/A | ★ 0.93 |
| Revenue | $55,180.00 | ★ $284,290,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | ★ N/A | $20.89 |
| Revenue Growth | N/A | ★ 5.49 |
| 52 Week Low | $1.41 | $12.25 |
| 52 Week High | $4.34 | $22.29 |
| Indicator | GANX | CMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 40.10 |
| Support Level | $1.56 | $17.81 |
| Resistance Level | $3.06 | $19.58 |
| Average True Range (ATR) | 0.18 | 0.69 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 82.59 | 0.00 |
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.